Last Updated on August 12, 2025 by The Health Master
USFDA inspection
Ahmedabad, India: Senores Pharmaceuticals Limited, a prominent global player in the pharmaceutical sector, recently confirmed that a United States Food & Drug Administration inspection (USFDA Inspection) has been conducted at its subsidiary, Havix Group Inc. D/B/A Aavis Pharmaceuticals, situated in Hoschton, Georgia, USA.
During the said USFDA inspection, the company received three observations on Form 483.
These three observations were pointed out during a routine USFDA inspection of Aavis Pharmaceuticals‘ manufacturing facility conducted between July 21 and July 25, 2025.
What are USFDA 483 Observations?
A USFDA observation on Form 483 is issued to a company’s management at the completion of a USFDA inspection when an inspector has observed deficiencies that may be considered as violations of the Food, Drug, and Cosmetic (FD&C) Act and related Acts.
It is worthwhile to mention here that these observations are not final conclusions of non-compliance but rather a preliminary notice of findings that require a company’s attention and quick response.
For pharmaceutical manufacturers, addressing these observations quickly is paramount to maintaining regulatory compliance and ensuring the quality and safety of the drug.
Senores Pharmaceuticals clarified the nature of these observations, stating, “These observations are procedural and minor in nature, and Havix will respond to these observations within 15 days.”
Senores Pharmaceuticals:
Senores Pharmaceuticals Limited is known to be a research-driven pharmaceutical company involved in the manufacturing of various dosage forms for many therapeutic areas.
The main focus of the company is on regulated markets such as the US and Canada, alongside a strong presence in emerging global markets.
Ensuring Pharmaceutical Quality:
The recent USFDA inspection and subsequent observations on Form 483 at the Aavis Pharmaceuticals facility highlight the continuous oversight inherent in the pharmaceutical company.
Regulatory bodies like the USFDA play an important role in ensuring the safety and efficacy of the drug manufactured by them.
The quick response by Havix Group Inc. shows the company’s commitment to resolving any issues and maintaining the quality of the products.
Q: What is the USFDA observation issued on Form 483?
A: A USFDA observation issued on Form 483 is a document issued by the USFDA mentioning the objectionable observations or practices observed by the inspectors during a USFDA inspection.
These observations are not considered as final conclusions of non-compliance but rather a preliminary notice of findings that require a company’s attention and response.
Q: Are observations on 483 observations serious issues?
A: Not necessarily. While some observations issued on Form 483 can be considered as “procedural and minor” in nature.
Disclaimer: This article contains information obtained from the source mentioned below. Our team made changes in the format to rewrite and present the news or article in a unique format.
USFDA inspection: At Unichem with 3 observations: Roha
USFDA inspection: At Natco Pharma with 7 observations: Hyderabad
USFDA inspection: At Sun Pharma with 8 observations: Halol
USFDA inspection: At Alembic Pharma with 4 observations: Panelav
Types of inspections done by USFDA: Read in detail
USFDA issues Form 483 to Pharma Companies: Let’s know all about it
Drug recall: Sun Pharma, Lupin, Dr. Reddy’s recall drugs
Ranitidine Under Scrutiny Over NDMA Concerns
NPPA directs Pharma industry on MRP of Non-Scheduled Formulations
All Medical Stores to install CCTV cameras: Delhi
India Inspects 905 Pharma firms: Action Against 694
Drug recall: Sun Pharma recalls 5,488 bottles of ADHD drug
Guidelines for Export NOC revised
Microbial contamination limits in Schedule M to be amended
